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Commentary
We are all exposed to thousands of natural
and man-made chemicals every day. Man-
made and naturally occurring chemicals are
present in the air, ingested food and water,
the workplace, and a number of consumer
products. The exposures that animals, plants,
and humans experience can be quite complex,
coming from a variety of potential sources
(Figure 1). The Centers for Disease Control
and Prevention (CDC), through its ongoing
National Health and Nutrition Examination
Survey (NHANES) project, has made it
increasingly clear that each of us has ingested,
inhaled, or absorbed a variety of these chemi-
cals, with many widely measured in blood or
urine in regions across the United States
(CDC 2005). Sampling and measuring these
chemicals and other agents is called “bio-
monitoring” (American Industrial Hygiene
Association 2004; DeCaprio 1997; Kamrin
2004; Metcalf and Orloff 2004). As a result
of well-conducted biomonitoring studies, we
can obtain a picture of the amount of a
chemical or agent actually absorbed into the
human body. Because of much-improved
tools and techniques discovered in the ﬁeld of
analytical chemistry, it is now possible to
detect extraordinarily low concentrations of
environmental chemicals in human tissue
(parts per trillion and parts per quadrillion).
Based on information from both toxicology
and epidemiology studies, most chemicals
that are currently detected in biomonitoring
programs of the general population are not
expected to produce adverse health effects at
the levels experienced in our society, although
for many chemicals more research is necessary
to afﬁrm this notion (CDC 2003, 2005).
Data from biomonitoring investigations
are becoming more widely available and are
frequently considered “newsworthy,” greatly
heightening public interest in these investiga-
tions (CDC 2005; San Mateo County
Environmental Health 2005; Williams 2005).
However, these data are often presented with-
out proper context, which can lead people to
the understandable but erroneous conclusion
that the low levels of chemicals found in our
tissues are harmful, simply by virtue of their
presence. In other words, detection does not
necessarily equal risk. Reporting data without
some type of explanation can frequently gen-
erate confusion and unnecessary anxiety. For
a few chemicals that are sometimes moni-
tored in manufacturing workers, we can
properly characterize the meaning of the data.
However, for most of the > 200 chemicals
that are now being monitored by the CDC and
other organizations, relating a chemical expo-
sure to a measurable health risk is problematic,
and we simply need to do more research to
properly inform the public (Keshava et al.
2005; Perera et al. 2005).
A relatively recent development in the
evolution of biomonitoring has been the
attempt to assess exposures of the general
population to chemicals found in the environ-
ment (“environmental” or “population bio-
monitoring”) (CDC 2003). Over time, one
can envision conducting biomonitoring of
indicators of biologic susceptibility to certain
industrial or pharmaceutical agents.
The selection of which chemicals to study
has been a complex and hotly debated topic.
The CDC has identiﬁed a number of impor-
tant variables that inﬂuence their nominating
process:
• Evidence of exposure in a U.S. population
• The presence and significance of health
effects after a given level of exposure
• Desire to track public health initiatives to
reduce exposure to a given agent
• Existing method for accurately measuring
biologically relevant concentrations of the
chemical
• Sufficient tissue specimens, in particular,
blood and/or urine samples
• Cost-effectiveness.
For their most recent report, the CDC
obtained nominations for hundreds of chemi-
cals and used a scoring process (CDC 2005). In
transitioning from exposure estimations to
direct biomonitoring, however, there will cer-
tainly be some obstacles. First, there are few
data regarding animal levels of chemical agents.
A fair comparison of animal data with human
data would seem to demand that we also obtain
internal levels in animals. Also, extrapolating
human measurements from one point in time
to chronic or even lifetime exposures may make
sense for agents with extremely long half-lives,
but for most agents one needs a series of data
points to accurately estimate chronic exposures
and any associated health risks.
Biologic Media Commonly
Analyzed
The new generation of analytical devices has
made it possible to search for and detect in
biologic tissue essentially any substance found
in the environment. For practical and ethical
considerations, only blood and urine have
generally been collected. Additionally, factors
such as exposure route, metabolism, and the
volatility of the chemical often dictate which
types of human samples can be most easily
analyzed (Needham et al 2005). The beneﬁts
and shortcomings of different sample types
are described below.
Whole blood/serum. Blood is commonly
used, largely because it is relatively easy to
collect, is regularly replenished, and is one of
the pathways through which most chemicals
and their metabolites travel within the body.
A disadvantage of using blood is that some
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drawn because of the invasiveness of phle-
botomy or their religious or cultural beliefs.
Additionally, because the life span of a red
blood cell is only around 90–120 days, past
exposures to some chemicals may be under-
estimated. This is especially true for those
chemicals that directly interact with the red
blood cell such as hexavalent chromium.
Urine. The collection of urine samples is
often the preferred method for biomonitoring
programs, but for most chemicals it is not a
reliable indicator of exposure. Only a few par-
ent compounds are excreted in the urine, so
typically one must test for excreted metabo-
lites. Sometimes, the chemicals that one
might want to study can also appear in the
urine of “unexposed” persons, such as ben-
zene in cigarette smokers. Toxicokinetics may
also be important because in many cases the
chemical of interest is excreted slowly over the
course of hours or days after exposure, mak-
ing it necessary to collect a 24-hr urine sam-
ple rather than a single sample. Timing of
sample collection may also be important
(Kissel et al. 2005). The primary advantage of
using urine is that it is noninvasive and there-
fore can be an attractive methodology for
conducting some large-scale studies.
Adipose tissue (fat). Adipose tissue studies
have, in the past, been used to study fat-soluble
chemicals. However, since about 1990, it has
been possible to obtain very similar informa-
tion about exposure from the fat-soluble frac-
tion of blood. For this reason, very few adipose
tissue samples are now collected.
Hair. Hair analysis techniques have
improved in recent years because of increasing
use by forensic scientists, especially in study-
ing drugs of abuse. Hair analysis has also been
applied to the study of certain environmental
chemicals such as mercury, arsenic, and man-
ganese. Of course, it is important to distin-
guish chemicals that are internally deposited
in hair from those that land on the hair and
are absorbed into it.
In addition, it is important that a careful
protocol be followed during the sampling and
analysis of human hair due to differing chemi-
cal concentrations along the length of the hair.
Few studies have measured occupational or
environmental exposure and then compared it
with results from hair analysis. By and large,
most investigators use hair analysis only as a
screening tool. A recent scientific panel that
evaluated the utility of hair sampling for assess-
ing exposure to chemicals routinely found in
the ambient environment concluded that the
method is too inconsistent to be relied upon,
with the possible exceptions of methylmercury
and arsenic (Harkins and Susten 2003). 
Breast milk. Breast milk can often provide
significant information about fat-soluble
chemicals in the environment. Nearly all of
the industrially signiﬁcant fat-soluble chemi-
cals, such as polychlorinated biphenyls
(PCBs), brominated flame retardants [poly-
brominated diphenyl ethers (PBDEs)], and
dioxins/furans can be measured in breast
milk. Samples of breast milk are relatively
easy to collect and may reﬂect historical expo-
sures to lipid-soluble chemicals found in the
environment. Diet plays a significant role,
with many of the chemicals in breast milk
arising from a mother’s consumption of ﬁsh,
meat, or dairy products. These can contain
small amounts of persistent, lipid-soluble
chemicals coming from deposition of dust,
vapors, or ash emitted from incinerators and
nearly every form of combustion, including
automobiles and furnaces.
Exposures to chemicals around the home
and in processed foods are also easily measured
in breast milk (Kamrin 2003). One can postu-
late that the breast-feeding infant is at the top
of this exposure chain. Because the infant has
such a small comparative body mass and
breast milk can compose a signiﬁcant fraction
of the diet for the ﬁrst year of life or longer,
there has been considerable interest in under-
standing the potential effects of these chemi-
cals in the developing infant. However, no
documented adverse effects from infant expo-
sures to typical levels of environmental chemi-
cals in breast milk have yet been identiﬁed. A
recent workshop explored a number of issues
surrounding biomonitoring, breast milk, and
risk assessment (LaKind et al. 2005).
Saliva and sputum. Saliva testing has not
been widely used, but it may hold promise as
a future noninvasive method for determining
exposure to some chemicals and has been
used by some laboratories to measure concen-
trations of naturally occurring steroid hor-
mones. Researchers have explored its use as a
monitor for therapeutic drug levels, with
mixed results (Madsen et al. 2004; Miles et al.
2003; Shiran et al. 2005) as well as for docu-
menting exposures to lead, pesticides, and cig-
arette smoke (Denovan et al. 2000; Lu et al.
2003; Timchalk et al. 2004, 2006; Woodward
et al. 2005). Saliva was ﬁrst used as early as the
1950s in assessing the exposure to some
chemicals in the workplace.
Sputum, on the other hand, has been used
in the past, but it has proved to be a much less
reliable data source, largely because of the
inconsistent quality of individual specimens.
The high variability in specimen quality can be
circumvented with invasive procedures, such as
transtracheal aspirates or suctioning material
through a bronchoscope or endotracheal tube,
but these techniques are not likely to be chosen
as screening techniques for the broader popula-
tion. Previous studies have evaluated sputum
for tracking exposure to asbestos, heavy metals,
and other inhalational agents (Josyula et al.
2006; Lemiere et al. 2001; McDonald et al.
1992; Paris et al. 2002; Park et al. 2003).
Semen. Semen has not yet been widely
used, but it is believed by some experts that
semen may turn out to be a better test medium
than many other bodily ﬂuids currently being
evaluated.
Exhaled air. This method is most applica-
ble in the study of volatile chemicals and some
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Figure 1. Pathways of elemental lead exposure to biologic media illustrating the complex relationship
between chemical release, exposure, and biologic media [modified from U.S. Environmental Protection
Agency (EPA) 1998].gases. Gustafsson et al. (1991) described the
measurement of nitric oxide in exhaled air, a
technique that now is used as a noninvasive
means of determining airway inﬂammation in
certain populations (American Thoracic
Society 2005). The noninvasive character and
reasonable expense generally associated with
the analysis of expired air make this an attrac-
tive option for a select subset of chemicals.
Sources of These Chemicals
The chemicals detected by biomonitoring
generally come from three types of sources:
anthropogenic or man-made processes, normal
biologic processes, and naturally occurring
chemicals in food.
Anthropogenic (relating to the activity of
humans). People may be exposed to man-made
chemicals as a result of their daily activities,
including working, using consumer products,
and eating. 
Persons working in certain occupations have
an increased likelihood for substantial exposure
to chemicals. Careful study of these individuals
has been invaluable in allowing scientists to bet-
ter understand the hazards posed by these agents
(Lan et al. 2004; Paustenbach et al. 1992). For
example, as a result of workplace exposures, we
know that elevated concentrations of certain
metals can increase the risk for a number of
acute illnesses such as neuropathies, kidney
damage, and liver damage. Since the organic
chemical revolution began in the 1920s, numer-
ous chemicals now in our environment possess a
long biologic half-life, and most of these can be
easily measured today.
Many consumer products contain lipid-
soluble chemicals, and these are readily
detectable because of their sequestration in
fatty tissues. Several of these chemicals are also
present in foods, which can make it difﬁcult to
attribute the exposure to a particular source.
In addition to indirectly influencing our
foods and the workplace, more generally the air
we breathe is a source of chemical exposure.
Respiratory effects of chemicals have attracted
signiﬁcant attention over the past few decades,
resulting in many regulatory initiatives (e.g.,
the Clean Air Act of 1990) with widespread
societal effects (reduced vehicle emissions,
burning restrictions, propellants and other
additives in consumer products, requirements
for cleaner fuels).
Normal biologic processes. Background
levels of many chemicals in blood or urine
occur as a result of normal biologic function.
For example, chemicals such as formaldehyde
and methanol are produced as a consequence
of normal human metabolism but can also
reflect exposure to industrial solvents, wood
products, or decomposition of biologic
wastes. When such duplicative sources are
possible, making the association of the labora-
tory data with exposure to a speciﬁc man-made
agent can be very difficult (Dettmer and
Hammock 2004).
Chemicals in food. Foods generally repre-
sent the largest source for chemicals found in
our bodies. Indeed, the World Health
Organization (WHO) believes that most
chronic health conditions can be attributed to
past and current exposure to chemicals in the
foods we eat (WHO 2005). Meat from graz-
ing animals contains chemicals present in the
plants they eat. These plants often contain
chemicals that came from the deposition of
particles released from combustion. In addi-
tion, vegetables contain naturally occurring
chemicals that bind to the aryl hydrocarbon
receptor (the same receptor necessary to initi-
ate dioxin toxicity) at a level > 45,000 times
greater than the dose of polychlorinated
dibenzo-p-dioxins (PCDDs), polychlorinated
dibenzofurans (PCDFs), and PCBs in a typi-
cal American diet (Connor et al. 2005; Finley
et al. 2003), although the half-lives of these
naturally occurring chemicals tend to be much
shorter. Similar results were reported by
Jeuken et al. (2003) in their study of dietary
herbal supplements and other common food
products. Finally, sometimes chemicals are
added during the processing of foods that then
show up in our diet or water supply.
Interpretation of
Biomonitoring Data
Currently, the standard method for estimating
exposure is to use mathematical models to
estimate the concentration of a chemical in
various media to which persons were thought
to have been exposed. To perform the calcula-
tion, researchers frequently collect information
on soil, water, air, dust, and food concentra-
tions and couple this with data on human
behaviors (how much air one breathes or food
one eats). All of the input parameters have
some degree of variability, potentially increas-
ing the degree of uncertainty in the answers
obtained. If properly conducted, this approach
may yield a reasonably accurate estimate of the
absorbed dose. However, without some con-
ﬁrmation of the exposure estimates through an
approved method of biologic sampling, it is
often not possible to validate the accuracy of
the exposure assessment.
By measuring the “body burden,” or total
amount of a chemical or its metabolites in the
human body, one can obtain direct evidence
of actual human exposure (Sexton et al.
2004). Unlike the data in other types of risk
assessments, biomonitoring requires no
assumptions regarding exposure parameters
such as ingestion or inhalation rate, bioavail-
ability, or frequency of exposure. It can also
provide speciﬁc information on an individual
regarding his or her particular set of expo-
sures. For example, dioxin levels in blood can
be a reﬂection of exposures that occurred over
the prior 20–25 years. It is usually not possi-
ble, however, to know whether the total
dioxin levels are primarily due to ingestion of
ﬁsh, meat, or dairy products over the previous
few months, or whether they are due to
chronic exposure from living near an indus-
trial facility. However, if one understands the
elimination rate of the speciﬁc chemical being
measured and can estimate the date(s) of last
exposure, then it may be possible to approxi-
mate the typical daily exposure that occurred
in the past and relate it to current results
(Aylward et al. 1996).
It is also important to recognize that
exposure to a potentially hazardous substance
does not necessarily result in clinical disease
or toxicity. For example, few persons are wor-
ried about the risk of ingesting two aspirin
tablets (650 mg) per day, but most know that
there can be serious adverse health effects
associated with ingesting a much higher dose,
say, ≥ 20 aspirin pills per day. Most, if not all,
toxicity studies provide information about the
relationship of daily dose and an adverse
health effect. In order to correlate toxicity
data with biomonitoring data, an estimate of
daily dose must be performed. If that can be
reasonably calculated, it may then be possible
to estimate the likelihood of an adverse health
effect and the severity of that effect.
One of the most signiﬁcant challenges in
biologic monitoring is characterizing the rele-
vance of the data. Detection alone means vir-
tually nothing because very low concentrations
of dozens of chemicals have been detected in
our environment for at least the past 50 years.
What is important is to discover whether or
not these trace concentrations are actually
exerting some measurable effect. This is cer-
tainly a complicated question because, on
average, Americans are living longer than ever
before and have much higher expectations
regarding their quality of life in the later years.
At the same time, however, the incidence of
certain cancers such as prostate cancer, breast
cancer, and melanoma is increasing (Edwards
et al. 2005), and chronic diseases such as
obesity and diabetes are also on the rise. By
comparing community blood levels with
appropriate animal or human studies examin-
ing the hazards posed by a speciﬁc chemical,
one can reasonably determine whether there
are increased health risks associated with envi-
ronmental exposure. It is also important to
recognize that some diseases (e.g., prostate
cancer or senile dementia) may be showing an
increased incidence simply because people are
living longer.
Other factors to be considered when
interpreting biomonitoring data include toxi-
cologic factors, such as validity of the toxico-
logic or epidemiologic study, toxicokinetic
considerations, adequacy of the sample size,
reproducibility of the sample, and presence of
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such as time since last exposure, average dose
received, and frequency of exposures. In certain
cases, a particular biomonitor may have been
widely used for many years, and the aforemen-
tioned factors may have been accounted for
and validated by a reputable scientific body.
Thus far, only a few biomarkers of environ-
mental chemicals have been through this level
of scrutiny and are considered useful in evalu-
ating the health of persons in the community.
Others, such as phenol in urine due to expo-
sure to benzene, dioxins in blood, urinary mer-
cury, and a number of others, have been useful
in studying workers. Because most criteria for
biologic monitoring are based on extrapola-
tions of animal or human data where exposures
were at very high concentrations, it is often not
possible to predict that an adverse effect will
occur in a speciﬁc individual or group of indi-
viduals who have a lower concentration of a
biomarker. Ideally, in future toxicologic stud-
ies, blood levels will be routinely measured and
compared with the delivered dose to facilitate
the interpretation of biomonitoring studies in
humans. One important challenge facing sci-
entists with respect to the use of biomonitoring
data is to ensure that appropriate normative
values are available to interpret test results.
Background levels, or the typical range of bio-
marker concentrations expected in the general
population, are fundamental for this analysis.
Some of these data have been compiled by
NHANES (CDC 2003, 2005).
The National Center for Environmental
Health (Atlanta, GA) has measured concentra-
tions of > 100 environmental chemicals in the
blood of the general population. These are
frequently reported as means and various
upper percentiles (e.g., the 95th percentile).
Although determining the percentile ranking
of an individual’s biomonitoring results does
not necessarily suggest that an adverse effect is
expected, a measurement markedly above the
95th or 99th percentile can alert scientists that
the individual is experiencing some unique
exposure that may be worth documenting and
characterizing. To understand the health risk,
however, one must compare this kind of infor-
mation with data collected in toxicologic
and/or epidemiologic studies. In a summary of
an interdisciplinary panel in 2004, Bates et al.
(2005) provide an excellent review of bio-
monitoring study design and many of the
issues around interpreting biomonitoring data.
Limitations
Information regarding exposure. The presence
of a biomarker does not reveal the source or
route of exposure. When there is only one
potential source of exposure to the chemical, for
example, cobalt in the diet, the challenge may
be minimal. However, in the case of dioxins,
there can be many different sources of exposure,
and sorting out the actual source will generally
be difﬁcult and sometimes impossible.
Appreciation of the wide variability in
chemical half-lives is also important. Some
chemicals, such as dioxins and PCBs, are fat
soluble and resistant to degradation. These
chemicals have biologic half-lives measured in
years (Table 1), which makes it feasible to
detect signiﬁcant exposures sometimes decades
after they occurred. Conversely, many metals,
volatile organic compounds, and water-soluble
compounds are rapidly eliminated from the
body, with half-lives of a few hours to a few
days. After exposure to such a chemical, it is
necessary to promptly collect the biologic sam-
ple before the chemical has been excreted. This
limits the feasibility of biomonitoring studies
for these types of chemicals. If the exposures
are intermittent and the biomarker is short-
lived, it is often difﬁcult to collect suitable sam-
ples for biomonitoring. For example, one study
attempted to look at the chemical toluene
diisocyanate (TDI) in a population with inter-
mittent exposures (Metcalf and Orloff 2004).
Because of TDI’s short half-life, biologic sam-
ples were not useful. Instead, investigators
measured antibodies to TDI, which have a
longer presence in the body. In some cases,
where chemicals are known to have a short
half-life and are widely measurable in the
population, this indicates a frequent, possibly
continuous exposure to the chemical of interest
(e.g., cotinine or some phthalates). For every
chemical involved in biomonitoring studies, it
is necessary to give considerable thought to the
toxicokinetics before one tries to interpret the
signiﬁcance of the data obtained.
Health consequences of chemical exposure.
For a few chemicals, such as lead, human data
from occupational and other clinical studies
allow us to identify body burdens of a chemi-
cal that may result in an adverse health effect.
This information can be used to justify reduc-
tion or removal of a particular chemical from
consumer products or cleanup and monitor-
ing of affected environments. Figure 2 demon-
strates the remarkable impact that regulatory
actions and public awareness have had on lead
levels in our society, after adequate scientiﬁc
recognition of the health effects of lead on
humans. For other chemicals, there may be a
suspicion of adverse effects, found perhaps in
animal studies or in case reports, but the
assembled evidence is not yet compelling. For
most chemicals, however, we do not have ade-
quate human data to be certain about health
effects, particularly at very low chemical con-
centrations. In addition, most environmental
exposures involve multiple substances, and
attributing cause to a single chemical can often
be difficult. These complexities should be
revealed to groups being studied before they
are allowed to give consent to participate in an
investigation.
Beneﬁts of Biomonitoring
Programs
Perhaps the primary benefit that can be
obtained from biomonitoring is the identiﬁca-
tion of long-term trends in the population.
For example, it has been observed that blood
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Figure 2. Sharp decline in human lead levels in the
United States, as demonstrated in the NHANES III
data set, compared with the levels predicted by
U.S. EPA calculations (CDC 2005; Needham 2005).
This decline continued for two decades.
Table 1. Half-lives of some exposure biomarkers.
Half-life Chemical Indicator Sample
Very short
2.5 hr Benzene Benzene Blood and exhaled air
3.5 hr Phenol Urine
5 hr Carbon monoxide Carboxyhemoglobin Blood
Short
5 hr Styrene Mandelic acid Urine
14 hr n-Hexane 2,5-Hexanedione Urine
18 hr Polycyclic hydrocarbons Pyrenol Urine
96 hr Perchloroethylene Perchloroethylene Blood and exhaled air
Long
18 days Mercury Mercury Blood and urine
30 days Lead Lead Blood
100 days Cadmium Cadmium Blood
Very long
2 years Hexachlorobenzene Hexachlorobenzene Serum
5 years Lead Lead Bones
7 years 2,3,7,8-TCDD 2,3,7,8-TCDD Blood
> 10 years Cadmium Cadmium Urine
2,3,7,8-TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. Modiﬁed from Santamaria (2005).levels of PBDEs have increased in the general
population over the past 10 years in the United
States [Agency for Toxic Substances and
Disease Registry (ATSDR) 2004; Stokstad
2004]. PBDE levels have also increased in
samples of human breast milk collected in
Sweden (Figure 3). However, other studies
have shown that the total body burden of
organohalogen compounds has actually been
decreasing over time (Meironyté et al. 1999;
Schecter et al. 2003). Comparing these obser-
vations encourages an understanding of why
the levels of PBDEs appear to be increasing
while the broader category of organohalogens
appears to be decreasing. Regulations propos-
ing the banning of PBDEs in consumer prod-
ucts exist in some European countries, based
primarily on the results of biomonitoring
studies. Proper interpretation of these data,
however, requires careful consideration of
dose, duration of exposure, and toxicity. After
performing appropriate studies, public health
policy makers and scientists then need to
decide whether reduction of chemical release
into the environment is necessary, and
whether the relatively higher U.S. levels of
PBDEs in breast milk noted in Figure 3 con-
stitute a true health hazard. Often, only one or
two sources may account for the vast majority
of the exposure, and sometimes these sources
can be signiﬁcantly reduced or eliminated.
Another potential beneﬁt of a national bio-
monitoring program is identifying those geo-
graphic locations where people have much
different body burdens than the general popu-
lation. For example, if the inhabitants of a par-
ticular coastal area have a higher than expected
concentration of PCBs, this might suggest that
there is a local source of exposure to PCBs that
is extraordinary. In this scenario, scientists
might conduct an evaluation of meat, ﬁsh, and
dairy products to determine whether diet is a
significant source for the chemical. If the
dietary intake is found to be within normal
ranges, then one might progress to a study
examining the possible historical or current
industrial sources of PCBs. After scientists have
obtained a good understanding of the variabil-
ity of typical background concentrations in the
nation, biomonitoring could identify “hot
spots” that deserve attention.
Biomonitoring data might also reveal
unusually elevated releases of environmental
chemicals. For example, one might identify a
speciﬁc community where half of the inhabi-
tants have concentrations of a persistent
chemical in their blood that is at the 95th
percentile of the national levels. This would
suggest a local source, and if some consistent
adverse effects were seen in this group, the
population could be studied to further
advance our understanding of the chemical
and its potential impact on society. Only a
few chemicals in the general population have
been studied in this way, such as lead and
arsenic, which led to guidelines regarding the
possible health risk associated with certain
concentrations found in blood or urine.
Properly conducted, biomonitoring could
also help deliver valuable evidence for epidemi-
ologic studies, which are frequently plagued by
weak exposure data. Biomonitoring would pro-
vide unequivocal evidence of exposure and be
able to yield quantitative information. The
importance of certain factors, such as age
group stratiﬁcation, can provide insights into
human exposures, particularly for chemicals
that have long half-lives (Figure 4). More
important, if the toxicokinetics and dermal
absorption are possible to obtain, they can pro-
vide speciﬁc data quantifying the magnitude of
exposure so that a dose–response relationship
can be properly characterized. Having these
data would greatly elevate the merit and possi-
ble impact of an epidemiologic study.
Biomonitoring can also reduce the uncer-
tainty inherent within traditional exposure
and risk assessments. In general, these assess-
ments have relied on calculations that attempt
to quantitatively account for intake of a
chemical as a result of soil ingestion, drinking
water, breathing the ambient air, ingesting
foods, or exposure to house dust, based on
estimates of concentrations of various chemi-
cals in the speciﬁc media. Many also rely on
experimental data from high-dose chemical
exposure studies in animals when estimating
the “safe” or tolerable dose and fail to account
for a variety of uncertainty factors in inter-
species variation. Biomonitoring data could
eliminate or reduce much of this uncertainty
in estimating risk because internal dose and
response information would be directly avail-
able for a human population.
Establishing statistical trends with bio-
monitoring data can aid in determining the
progress of speciﬁc policy decisions to reduce
or eliminate particular compounds in the envi-
ronment or occupational setting. For example,
blood lead levels in the United States have
dropped > 90% with the elimination of lead as
a gasoline additive (Figure 2); PCB levels have
also consistently declined in the last 20 years
as PCBs have been phased out by industry
(Kamrin 2003; Metcalf and Orloff 2004). The
same phenomenon has been observed with
DDT (dichlorodiphenyltrichloroethane),
chlordane, and heptachlor. Scientists had a
sense that reductions of these chemicals in the
general environment would lessen body bur-
dens in our society, but the time frame over
which this would occur and the magnitude of
its decline would not have been clear were it
not for biomonitoring programs.
How Biomonitoring 
Will Cause Change
Improving and protecting human health have
always been important ideals. The tools that
scientists have had at their disposal to measure
toxicants in our environment, understand their
possible impact on biochemical processes, and
evaluate their cumulative effects on people,
animals, water, air, food, and soils have
evolved rapidly, especially in the last decade.
Biomonitoring also allows insight into what a
speciﬁc individual has experienced, and how
his or her exposures may lead to an increased
risk of morbidity or mortality.
The penetration of biomonitoring into
our social fabric has generated a wholesale
shift in focus from the environment as a
model for human exposure—a method that
requires approximations regarding concentra-
tion, length of exposure, frequency of expo-
sure, “susceptibility,” absorption, distribution,
metabolism, and excretion—to a focus on the
individual. Scientists are now able to under-
stand how exposure translates into absorption
of a particular substance into various tissues of
the body. As we have observed with the
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Figure 4. Toxic equivalent (TEQ) levels of PCDDs/
PCDFs and select PCBs (congeners 81, 126, and 169)
measured in 45–59 year (A; PEI range = 36th–89th
percentile of age-speciﬁc NHANES) and ≥ 60 year
(B; PEI range = 12th–93rd percentile of age-speciﬁc
NHANES) age groups from the NHANES data set
(CDC 2005). Abbreviations: Max, maximum; Min, mini-
mum; PEI, pilot exposure investigation. Note the
higher levels found in the ≥60 year age group.
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Figure 3. Trend of increasing concentrations of
BDE-47 (2,2´,4,4´-tetraBDE), one of the PBDE con-
geners most frequently detected in breast milk
samples collected in Sweden and the United
States. Based on data from Meironyté et al. (1999)
and Schecter et al. (2003).NHANES initiative, scientists are now able to
measure hundreds of chemicals in members
of our society and compare the results across a
variety of geographic regions, age brackets,
and personal habits. We can subdivide the
data by sex, by racial background, by socio-
economic group—our limits increasingly have
become not mechanical, but instead prag-
matic. That is, which substances are consid-
ered most likely to be linked to disease or
dysfunction? Who should we examine? How
much will it cost to perform the study? How
do we go about rectifying the problem if we
determine that one exists?
With scientific or technologic advance-
ment comes responsibility. As scientists, we
should have a commitment to not just provid-
ing data but also to providing perspective. Our
viewpoints need to help shape reasonable deci-
sion making by our leaders and avoid alarmist
interpretations of data by those who would
seek to distort for their own ends. On the
other hand, we must also be attentive to sig-
niﬁcant health effects that can be meaningfully
related to a given exposure or set of exposures.
Before the “tide” of measuring chemicals
hits the public and an increasingly anxious
citizenry creates a demand for home mass
spectrometers, our public health leaders and
governmental agencies have a duty to inform,
to help people appreciate that our ability to
detect far surpasses our ability to detect mean-
ing. To properly ascertain the risk of a given
biologic level of a chemical will require well-
controlled studies that demand resources,
time, and careful planning. In an era of cost
containment at the federal, state, and local
levels, the process of committing our scarce
resources in the most effective manner possi-
ble will be of paramount importance.
Conclusion
Biomonitoring programs are likely to produce
a sea of change with respect to increasing the
awareness of the public to the presence of
chemicals in our diet and environment. In
addition, it is about to revolutionize, and per-
haps marginalize, the importance of much of
environmental monitoring as a screening tool.
It can be expected that biomonitoring will
become the ﬁrst indicator of concern and that
environmental measurements will be used to
identify the source of the contamination.
Currently, data are being shared in the
press and on the Internet without discussion of
their significance to human health. Indeed,
characterizing the signiﬁcance of these data to
the overall healthfulness of the public is a
daunting task that no organization appears
ready to tackle. In many cases, until a baseline
data set is well established, there is not a great
deal that can be safely concluded without con-
ducting a fairly careful risk assessment. It is
probably safe to say that virtually all scientists
agree that there needs to be a greater under-
standing of the potential risks to human health
posed by the various chemicals to which
Americans are exposed on a daily basis. It is
important, however, to use biomonitoring as a
tool to help guide our social and scientiﬁc lead-
ers to make intelligent decisions rather than as
a method for producing fear. Thus, the scien-
tiﬁc and regulatory communities need to begin
to initiate programs for communicating effec-
tively with the public about these data.
Biomonitoring, in its broadest sense,
offers great opportunities for identifying per-
sons who are unknowingly exposed to both
naturally occurring and industrial chemicals.
Currently, because most biomonitoring infor-
mation is designed to characterize back-
ground levels of a subset of chemicals in the
U.S. population, those conducting these pro-
grams must be aware of the unintended con-
sequences of sharing data that frequently are
insufficient to inform us of the presence of
increased risk. In our view, scientists have a
responsibility not only to do the hard work of
relating concentration with the toxicology
and epidemiology data but also to begin con-
ducting risk–risk tradeoff analyses, an exercise
that has been well developed over the past
20 years. These techniques offer the opportu-
nity to provide the public with the means to
sensibly decide how to balance the presence of
chemicals in the environment versus the pos-
sible risks. It is time for those of us in public
health to do a more thorough job of using all
of our knowledge about risk assessment and
risk beneﬁt in helping to inform everyone.
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